Realistic article As coronavirus restrictions around

New Post Public Reply Private Reply Replies (1) Message Board
reallypeople?
649
Realistic article

As coronavirus restrictions around the world are being lifted, a new report warns the pandemic that has already killed more than 230,000 people likely won't be contained for two years. The modeling study from the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota also says that about 70% of people need to be immune in order to bring the virus to a halt.

For the study, experts looked at eight major influenza pandemics dating back to the 1700s, as well as data about the new coronavirus, to help forecast how COVID-19 may spread over the coming months and years. Out of the eight past flu pandemics, scientists said seven had a second substantial peak about six months after the first one. Additionally, some had "smaller waves of cases over the course of 2 years" after the initial outbreak.

A key factor in their prediction for the current pandemic revolves around herd immunity, which refers to the community-wide resistance to the spread of a contagious disease that results when a high percentage of people are immune to it, either through vaccination or prior exposure.

"The length of the pandemic will likely be 18 to 24 months, as herd immunity gradually develops in the human population," the report says. "Given the transmissibility of SARS-CoV-2" — the virus that causes COVID-19 — "60% to 70% of the population may need to be immune to reach a critical threshold of herd immunity to halt the pandemic."

It will take time to reach that point, since data from blood tests show only a small fraction of the overall population has been infected so far, and a possible vaccine is still months if not a year or more away. It is not yet clear whether people who've recovered from the infection will be immune or how long such protection would last.

The report lays out several possible scenarios, including one in which a larger wave of illnesses may happen in the fall or winter of 2020 and then subsequent smaller waves in 2021. The researchers say this model — similar to the pattern seen in the devastating 1918 Spanish flu pandemic — would "require the reinstitution of mitigation measures in the fall in an attempt to drive down spread of infection and prevent healthcare systems from being overwhelmed."

Two other scenarios in the report involve either recurring peaks and valleys of outbreaks, or smaller waves of illness over the next two years.

In any case, the researchers said people must be prepared for "at least another 18 to 24 months of significant COVID-19 activity, with hot spots popping up periodically" in different geographic areas.

As the virus continues to circulate among the human population and outbreaks finally start to wane, they say it will likely "synchronize to a seasonal pattern with diminished severity over time."

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Black Friday Doubt Grows: Just 54% Trust Real Deals

Updated Category News Views 127

Do Shoppers Believe in Black Friday Anymore? You'd think by now, retailers would have cracked the code on building trust with their customers. But guess what? A fresh survey from Boston Consulting Group reveals only 54% of consumers buy the whole Black Friday discount story. That's barely more than flipping a coin. Promotion Fatigue: The Trust Buster Funny thing,...

Continue Reading
Young Storytellers Honored: Bridging Cultures Through Journalism

Updated Category News Views 6

Leaders of Tomorrow: Campus News Awards 2026 It's no small feat to look at a room full of young journalists and see the future of how stories will be told. But that's exactly what happened at the Campus News Awards 2026 in Shenzhen. Here, kids from Hong Kong, Macao, Taiwan, and Southeast Asia stood proudly with their certificates, ready to tackle the changing landscape of...

Continue Reading
TSX Surges Amid Earnings Wave and Market Momentum

Updated Category News Views 46

TSX Soars, But What's Driving the Surge? Gotta say, when the TSX leaps over 2% in a single day, it sets the stage for two things: excitement and scrutiny. On a balmy Wednesday, Canada's stock market stood tall at 36,317.67, up 785.39 points. Wall Street joined the dance too, with the Dow kicking up by 1,543.75 points. Good vibes all around — but hang on a minute. You...

Continue Reading
Marini SkinSolutions Wins with Night Zyme Complex

Updated Category News Views 13

Shaking Up the Skincare Scene You don't often see a skincare product snag three prestigious awards in one year, but that's exactly what's unfolding for Marini SkinSolutions. This time, their Night Zyme® Overnight Glass Skin Resurfacing Complex grabbed the 2026 Shop TODAY Ageless Beauty Award. It’s turning heads and not just in beauty aisles but among investors eyeing a...

Continue Reading
Defense Contractors Eye Larger Backlogs Amid Funding Uncertainty

Updated Category News Views 144

Playing Chicken with Federal Deadlines We've got ourselves a situation where defense contractors are juggling bigger backlogs while the clock ticks down to a looming federal funding deadline on December 11. If this sounds like a high-stakes game of chicken, it's because it is. No one knows if Congress will stitch things up before the stopgap funding dries up. Hell, maybe...

Continue Reading
MAURE's Three-Year Mark: Crafting Home Elegance

Updated Category News Views 39

Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...

Continue Reading
Trimble's Q3 2026: Guidance Update and Record ARR

Updated Category News Views 89

Trimble Smashes Through Q3 Expectations Trimble Inc. (NASDAQ:TRMB) tossed a bit of a curveball by posting Q3 2026 results that sailed past analyst forecasts. We’re talking revenue swelling to $966.8 million, a decent 7% bump from the previous year. Now, for a company riding its 'Connect & Scale' strategy, this serves as a validation of its aggressive scaling ambitions....

Continue Reading
Duolingo Faces Class Action: Investors React Strongly

Updated Category News Views 63

Duolingo's Rough Road: A Lawsuit in Motion Alright, fasten your seatbelts, because we've got a real rollercoaster here with Duolingo (NASDAQ: DUOL). You know, the language-learning app that's been pushing ads like it's going out of style? Well, investors are seeing red—not the kind you want, either. This class action lawsuit looming over them is like an unwelcome...

Continue Reading
Natixis' $100M Student Challenge Mixes Real Stakes

Updated Category News Views 127

Opportunity Knocks for Budding Portfolio Managers Picture this: You're a student, neck-deep in textbooks and theories, and then bam! You're handed the keys to manage a $100 million portfolio. That's the real-deal opportunity Natixis Investment Managers is dangling with its seventh Students Challenge. Diving Into the Nuts and Bolts Listen up, kids. Applications are open...

Continue Reading
NACCO Navigates Strong 2026 Q3, Faces Solar Cost Hurdles

Updated Category News Views 34

Rolling With NACCO's Financial Punches Well, folks, when it rains, it pours—numbers that is. NACCO Industries just laid out their Q3 results for all to gawk at, and it's a mixed bag of triumphs and tussles. You got a gross profit of $11.8 million, a sweet 18% jump on the same quarter last year. Now, you're talking about revenue muscle, and there it is. Income before...

Continue Reading

Top 5 Most Recently Viewed Articles

Vantiva Launches Cutting-Edge DOCSIS 4.0 FDD Cable Modem

Updated Category News Views 825

Vantiva Unveils Game-Changing DOCSIS 4.0 FDD Modem Vantiva, a prominent name in technology solutions, has introduced the Marlin Xe (CXA500Z), the first commercially available DOCSIS 4.0 Frequency Division Duplex (FDD) Cable Modem. This groundbreaking product is designed to allow service providers to deliver outstanding data speeds that rival the performance of...

Continue Reading
AST Welcomes Jacob Stephen as New Chief Operating Officer

Updated Category News Views 194

AST Welcomes Jacob Stephen as Chief Operating Officer Stephen to lead company-wide execution, strengthening AST's Executive Leadership Team AST is thrilled to announce that Jacob Stephen will be joining the AST Team as Chief Operating Officer at the drug product equipment manufacturing company headquartered in Tacoma. Jacob joins from IPS, where he excelled as Head of...

Continue Reading
Celebrating Bravery: Broward Sheriff's Heroes Recognized

Updated Category News Views 244

Ceremony Highlights Bravery and Dedication The Broward Sheriff's Advisory Council recently hosted a remarkable event dedicated to honoring the exceptional bravery and commitment of first responders in the community. This annual Tribute to Bravery ceremony took place at a beautiful venue by the beach, bringing together heroes and supporters alike. Acknowledging Local...

Continue Reading
Insight into Recent Riksbank Government Bond Auctions

Updated Category News Views 194

Overview of Riksbank Auctions for Government Bonds The Riksbank, Sweden's central bank, frequently holds auctions for government bonds as a way to manage monetary policy and influence the economy. These auctions are significant for investors, economists, and financial analysts who closely monitor the outcomes, as they provide insights into market sentiment and interest...

Continue Reading
Innovative Approaches in Neuroblastoma Treatment by Y-mAbs

Updated Category News Views 235

Y-mAbs Shares New Developments in Neuroblastoma Treatment Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a leading biopharmaceutical company dedicated to advancing cancer therapies, has announced exciting new research focused on treating neuroblastoma through innovative technologies. Recent clinical and preclinical findings related to naxitamab and the GD2-SADA platform were...

Continue Reading